BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 28733935)

  • 21. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 22. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
    Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
    Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
    Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
    Liang Y; Yu XJ; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
    Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
    Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
    Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
    Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?
    Merola E; Zandee W; de Mestier L; Klümpen HJ; Makulik K; Geboes K; van Velthuysen ML; Couvelard A; Cros J; van Eeden S; Hoorens A; Stephenson T; Zajęcki W; de Herder W; Munir A
    Neuroendocrinology; 2021; 111(1-2):170-177. PubMed ID: 32155627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
    Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
    Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.
    Klimstra DS
    Endocrine; 2016 Jul; 53(1):4-6. PubMed ID: 27150611
    [No Abstract]   [Full Text] [Related]  

  • 37. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
    Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
    Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
    Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
    Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.